How to Test Human-Specific Combination Immunotherapies In Vivo
Por um escritor misterioso
Descrição
Learn how to evaluate combinations of human-specific checkpoint inhibitors in vivo, with double knock-in humanized drug target mouse models.
Frontiers Clinical cancer immunotherapy: Current progress and prospects
Frontiers Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More
A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases - eBioMedicine
Multimodal analysis for human ex vivo studies shows extensive molecular changes from delays in blood processing - ScienceDirect
Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer
Role of NK cells to treat B-Cell Lymphoma
Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy
Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity
State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation
Development of humanized mouse with patient‐derived xenografts for cancer immunotherapy studies: A comprehensive review - Jin - 2021 - Cancer Science - Wiley Online Library
IJMS, Free Full-Text
de
por adulto (o preço varia de acordo com o tamanho do grupo)
